Inovio Pharmaceuticals Inc vs Seagate Technology Holdings PLC — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Seagate Technology Holdings PLC trades at $879.08 (market cap $185.97B). The key difference: Seagate Technology Holdings PLC is far larger — about 2367.5× Inovio Pharmaceuticals Inc's market cap, and Seagate Technology Holdings PLC pays a 0.36% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | STX | |
|---|---|---|
Market Cap | $78.55M | $185.97B |
Sector | Health | Technology |
52-Week High | $2.87 | $1.09K |
52-Week Low | $0.66 | $154.43 |
Enterprise Value | $49.56M | $188.12B |
Dividend Yield | — | 0.36% |
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Seagate Technology (STX) trades at $879.11, up 9.79% in 24 hours, reflecting strong momentum driven by AI storage demand. The stock shows a neutral technical signal with support near $803 and resistance at $833. Recent earnings beats and a projected 2026 net income margin of 26.1% highlight robust fundamentals, though elevated valuation ratios like a P/E of 59.03 warrant caution. Positive analyst sentiment, with 55% buy ratings and a consensus price target of $1,130, underscores growth optimism amid AI-driven data center expansion.
Outlook: STX benefits from AI storage tailwinds and disciplined supply, but high debt and valuation pose risks. The stock offers growth potential if execution continues, yet volatility from memory market cycles and competitive pressures requires monitoring. Investor focus remains on HAMR technology adoption and sustained margin improvement.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →